Paradigm Biopharmaceuticals Ltd has released a press release.
Quarterly Cashflow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Recruitment complete in Paradigms hay fever clinical trial
- Paradigms hay fever clinical trial cleared to commence
- Appendix 4C - September 2016 quarter
- Paradigms Placement heavily oversubscribed
- Preclinical study underpins efficacy of Paradigms RhinosulR
Later from Paradigm Biopharmaceuticals
- Paradigm Update Ross River Virus Clinical Trial
- Paradigm receives $1.34 million R&D tax incentive rebate
- Final participant treated in Phase 2 hay fever trial
- Paradigm March Quarter Update & Appendix 4C
- Paradigm Government grant for Ross River virus research
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals